Novo Nordisk announced it has reached an agreement with the US Justice Department and two citizens to settle an investigation into alleged unfair trade practices regarding the anti-bleeding drug NovoSeven, which was allegedly the object of improper promotion for unapproved uses: under the agreement, Novo Nordisk, which denies all charges, will pay $ 25 million to settle the case, a company statement announced.
The company added that it "does not recommend or promote 'off-label' use of the drugs and in fact actively works with the FDA to address safety concerns when physicians, exercising their professional judgment, use NovoSeven outside the approved indications."
Novo Nordisk also agreed to pay just over $1.7 million to the US government to settle allegations of fraudulent practices to be included in the Medicaid program. The accusation concerns the marketing of the insulin-based products Novolin and Novolog: it seems that some scientific representatives of the drug Novo Nordisk paid pharmacists to recommend the medicines and had access to confidential information on the patients. Again, Novo denies all allegations.
June 14, 2011 – Pharmakronos
